⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
REGN News
Regeneron Pharmaceuticals Inc
Global Cancer Immunotherapy Market Report 2026 | Industry to Reach $311.43 Billion by 2031, Driven by Precision Oncology and Cell Therapy Innovation
globenewswire.com
AMGN
AZN
BMY
MRK
PFE
NVS
GSK
LLY
ABBV
JNJ
REGN
SNY
BE
BNTX
MRNA
IOVA
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN
globenewswire.com
REGN
Class Action Alert: Levi & Korsinsky Reminds Regeneron (REGN) Investors of September 14, 2026 Deadline
accessnewswire.com
REGN
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
prnewswire.com
REGN
Securities Lawsuit Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors - Contact Levi & Korsinsky Before September 14, 2026
accessnewswire.com
REGN
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
accessnewswire.com
REGN
Pomerantz LLP Issues Reminder to Shareholders in Regeneron Pharmaceuticals, Inc. of Class Action Filing – REGN
accessnewswire.com
REGN
Levi & Korsinsky Urges Regeneron Pharmaceuticals, Inc. (REGN) Shareholders to Act Before Lead Plaintiff Deadline September 14, 2026
accessnewswire.com
REGN
Pomerantz LLP Calls Attention to Class Action Filed Against Regeneron Pharmaceuticals, Inc. – REGN
accessnewswire.com
REGN
Contact Levi & Korsinsky by September 14, 2026 to Join Class Action Against Regeneron Pharmaceuticals, Inc. (REGN)
accessnewswire.com
REGN